Page last updated: 2024-10-28
hydroxyurea and Arterial Diseases, Carotid
hydroxyurea has been researched along with Arterial Diseases, Carotid in 2 studies
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Treatment with hydroxyurea and CTT were obtained from the chart review." | 1.72 | Evolution of Extracranial Internal Carotid Artery Disease in Children With Sickle Cell Anemia. ( Alison, M; Balandra, S; Belarbi, N; Bernaudin, F; Cussenot, I; Elmaleh, M; Ithier, G; Kheniche, A; Ntorkou, A; Oloukoi, C; Ouaziz, H; Sekkal, A; Tanase, A; Verlhac, S, 2022) |
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Verlhac, S | 1 |
| Ithier, G | 1 |
| Bernaudin, F | 1 |
| Oloukoi, C | 1 |
| Cussenot, I | 1 |
| Balandra, S | 1 |
| Kheniche, A | 1 |
| Ntorkou, A | 1 |
| Ouaziz, H | 1 |
| Tanase, A | 1 |
| Sekkal, A | 1 |
| Belarbi, N | 1 |
| Elmaleh, M | 1 |
| Alison, M | 1 |
| Gaztanaga, J | 1 |
| Farkouh, M | 1 |
| Rudd, JH | 1 |
| Brotz, TM | 1 |
| Rosenbaum, D | 1 |
| Mani, V | 1 |
| Kerwin, TC | 1 |
| Taub, R | 1 |
| Tardif, JC | 1 |
| Tawakol, A | 1 |
| Fayad, ZA | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Effect of VIA-2291, a 5-Lipoxygenase Inhibitor, on Vascular Inflammation in Patients After an Acute Coronary Syndrome Event[NCT00552188] | Phase 2 | 52 participants (Actual) | Interventional | 2007-10-31 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Change From Baseline in Plaque Imaging After 24 Weeks
To evaluate the effect of VIA-2291 100 mg relative to placebo on the change from baseline in the target (plaque) to background (blood) ratio (TBR) from an index vessel (either right carotid, left carotid or ascending aorta) based on the standardized 18fluorodeoxy glucose (FDG) uptake measured with PET in patients with acute coronary syndrome and vascular inflammation after 24 weeks of daily dosing. (NCT00552188)
Timeframe: Baseline and 24 Weeks
| Intervention | TBR (Least Squares Mean) |
|---|
| VIA-2291 | -0.01 |
| Placebo | -0.06 |
Change From Baseline in Plaque Imaging After 6 Weeks
To evaluate the effect of VIA-2291 100 mg relative to placebo on the change from baseline in the TBR from an index vessel (either right carotid, left carotid or ascending aorta) based on the standardized 18FDG uptake measured with PET in patients after 6 weeks of daily dosing. (NCT00552188)
Timeframe: Baseline and 6 Weeks
| Intervention | TBR (Least Squares Mean) |
|---|
| VIA-2291 | 0.01 |
| Placebo | -0.07 |
Trials
1 trial available for hydroxyurea and Arterial Diseases, Carotid
Other Studies
1 other study available for hydroxyurea and Arterial Diseases, Carotid